PMD 📈 Psychemedics - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US7443752057
PMD: Hair Analysis Tests, Substance Abuse Screening Services
Psychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. It offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, fentanyl and fentanyl analogs, and alcohol. The company's testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. It offers its services to employers for job applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. The company was incorporated in 1986 and is headquartered in Dallas, Texas. Web URL: https://www.psychemedics.com
Additional Sources for PMD Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
PMD Stock Overview
Market Cap in USD | 16m |
Sector | Healthcare |
Industry | Diagnostics & Research |
GiC Sub-Industry | Health Care Services |
IPO / Inception | 1994-02-17 |
PMD Stock Ratings
Growth 5y | -82.0% |
Fundamental | -44.6% |
Dividend | 11.6% |
Rel. Strength Industry | -207 |
Analysts | - |
Fair Price Momentum | 2.47 USD |
Fair Price DCF | 2.40 USD |
PMD Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | % |
Annual Growth 5y | -100.00% |
Payout Consistency | 86.0% |
PMD Growth Ratios
Growth Correlation 3m | 71.5% |
Growth Correlation 12m | -74.9% |
Growth Correlation 5y | -63.1% |
CAGR 5y | -20.78% |
CAGR/Mean DD 5y | -0.44 |
Sharpe Ratio 12m | 0.09 |
Alpha | -25.97 |
Beta | 0.54 |
Volatility | 210.82% |
Current Volume | 113.6k |
Average Volume 20d | 60.2k |
What is the price of PMD stocks?
As of December 22, 2024, the stock is trading at USD 2.67 with a total of 113,627 shares traded.
Over the past week, the price has changed by +0.00%, over one month by +14.10%, over three months by +14.59% and over the past year by -6.32%.
As of December 22, 2024, the stock is trading at USD 2.67 with a total of 113,627 shares traded.
Over the past week, the price has changed by +0.00%, over one month by +14.10%, over three months by +14.59% and over the past year by -6.32%.
Is Psychemedics a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Psychemedics (NASDAQ:PMD) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -44.56 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PMD as of December 2024 is 2.47. This means that PMD is currently overvalued and has a potential downside of -7.49%.
Probably not. Based on ValueRay Fundamental Analyses, Psychemedics (NASDAQ:PMD) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -44.56 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PMD as of December 2024 is 2.47. This means that PMD is currently overvalued and has a potential downside of -7.49%.
Is PMD a buy, sell or hold?
Psychemedics has no consensus analysts rating.
Psychemedics has no consensus analysts rating.
What are the forecast for PMD stock price target?
According to ValueRays Forecast Model, PMD Psychemedics will be worth about 2.7 in December 2025. The stock is currently trading at 2.67. This means that the stock has a potential upside of +0.75%.
According to ValueRays Forecast Model, PMD Psychemedics will be worth about 2.7 in December 2025. The stock is currently trading at 2.67. This means that the stock has a potential upside of +0.75%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 32 | 1098.5% |
Analysts Target Price | - | - |
ValueRay Target Price | 2.7 | 0.7% |